| Ironwood Family Practice, Pa | |
|
920 W Ironwood Dr Ste 101 Coeur D Alene ID 83814-2464 | |
| (208) 667-4557 | |
| (208) 765-2887 |
| Full Name | Ironwood Family Practice, Pa |
|---|---|
| Speciality | Family Medicine |
| Location | 920 W Ironwood Dr Ste 101, Coeur D Alene, Idaho |
| Authorized Official Name and Position | Nina Everson (ADMINISTRATOR) |
| Authorized Official Contact | 2086674557 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ironwood Family Practice, Pa 920 W Ironwood Dr Coeur D Alene ID 83814-2463 Ph: (208) 667-4557 | Ironwood Family Practice, Pa 920 W Ironwood Dr Ste 101 Coeur D Alene ID 83814-2464 Ph: (208) 667-4557 |
| NPI Number | 1083650931 |
|---|---|
| Provider Enumeration Date | 06/21/2006 |
| Last Update Date | 08/03/2023 |
| Medicare PECOS PAC ID | 3971698424 |
|---|---|
| Medicare Enrollment ID | O20070928000526 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083650931 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (Idaho) | Primary |
| Provider Name | David L Chambers |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700857729 PECOS PAC ID: 7416840012 Enrollment ID: I20040206000318 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Timothy Burns |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1609847615 PECOS PAC ID: 3476446998 Enrollment ID: I20040206000524 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Geoffrey T Emry |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902891518 PECOS PAC ID: 7012992241 Enrollment ID: I20040622001008 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Brittany C Burns |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730395310 PECOS PAC ID: 4880752773 Enrollment ID: I20081021000864 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Jessica Capaul |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457721011 PECOS PAC ID: 6709195167 Enrollment ID: I20151026001527 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Hollie Mills |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871905562 PECOS PAC ID: 4385960194 Enrollment ID: I20170802003410 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Leah M Weatherly |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1881127330 PECOS PAC ID: 9436572666 Enrollment ID: I20200707002358 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Mark C Walsworth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1235798067 PECOS PAC ID: 7911385497 Enrollment ID: I20220613001550 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Aaron T Drapeau |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780152959 PECOS PAC ID: 3971968439 Enrollment ID: I20230505001037 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Justin M Thompson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1952922999 PECOS PAC ID: 2961860374 Enrollment ID: I20230616001139 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
| Provider Name | Doreen M Krause |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659653301 PECOS PAC ID: 5597083303 Enrollment ID: I20231003001766 |
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
News Archive
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
Sun Pharmaceutical Industries Ltd. today announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration. CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
A unique opportunity made it feasible for uninsured patients with end-stage renal disease (ESRD) who received emergency-only dialysis in Dallas, Texas, to enroll in private, commercial health insurance plans in 2015 and that made it possible for researchers to compare scheduled vs. emergency-only dialysis among undocumented immigrants with ESRD.
New ESC Guidelines on pericardial diseases are published today. Until now there was insufficient evidence for strong recommendations in this group of conditions which can severely restrict quality of life.
› Verified 2 days ago
Cinch Health Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6190 N Sunshine St Ste E, Coeur D Alene, ID 83815 Phone: 208-691-4569 | |
Pmr Healthcare Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 210 E Sherman Ave Ste 204, Coeur D Alene, ID 83814 Phone: 208-664-6464 | |
Helping Hands Chiropractic And Wellness Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 116 W Neider Ave Unit 116, Coeur D Alene, ID 83815 Phone: 208-664-0444 Fax: 208-664-0446 | |
Head Sport Em Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 980 W Ironwood Dr Ste 206, Coeur D Alene, ID 83814 Phone: 208-512-4334 | |
After Hours Urgent Care Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 700 W Ironwood Dr, Suite 170e, Coeur D Alene, ID 83814 Phone: 208-676-1852 | |
Apple Family Care Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 980 W Ironwood Dr, Suite 201, Coeur D Alene, ID 83814 Phone: 208-292-1315 Fax: 208-765-0627 |